135 related articles for article (PubMed ID: 17413189)
1. Diagnostic imaging of dopamine receptors in pituitary adenomas.
de Herder WW; Reijs AEM; Feelders RA; van Aken MO; Krenning EP; van der Lely AJ; Kwekkeboom DJ
Eur J Endocrinol; 2007 Apr; 156 Suppl 1():S53-S56. PubMed ID: 17413189
[TBL] [Abstract][Full Text] [Related]
2. Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas.
de Herder WW; Reijs AE; de Swart J; Kaandorp Y; Lamberts SW; Krenning EP; Kwekkeboom DJ
Eur J Nucl Med; 1999 Jan; 26(1):46-50. PubMed ID: 9933661
[TBL] [Abstract][Full Text] [Related]
3. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW
Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
[TBL] [Abstract][Full Text] [Related]
4. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
Ferone D; Lastoria S; Colao A; Varrella P; Cerbone G; Acampa W; Merola B; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
Pirker W; Riedl M; Luger A; Czech T; Rössler K; Asenbaum S; Angelberger P; Kornhuber J; Deecke L; Podreka I; Brücke T
J Nucl Med; 1996 Dec; 37(12):1931-7. PubMed ID: 8970508
[TBL] [Abstract][Full Text] [Related]
6. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
7. Iodine-123-IBZM-SPECT: studies in 15 patients with pituitary tumors.
Pirker W; Brücke T; Riedl M; Clodi M; Luger A; Asenbaum S; Podreka I; Deecke L
J Neural Transm Gen Sect; 1994; 97(3):235-44. PubMed ID: 7873131
[TBL] [Abstract][Full Text] [Related]
8. Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?
de Herder WW; Reijs AE; Feelders RA; van Aken MO; Krenning EP; Tanghe HL; van der Lely AJ; Kwekkeboom DJ
Eur J Endocrinol; 2006 Nov; 155(5):717-23. PubMed ID: 17062888
[TBL] [Abstract][Full Text] [Related]
9. Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging.
Leslie WD; Abrams DN; Greenberg CR; Hobson D
J Nucl Med; 1996 Oct; 37(10):1589-91. PubMed ID: 8862288
[TBL] [Abstract][Full Text] [Related]
10. In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas.
Scillitani A; Dicembrino F; Di Fazio P; Vettori PP; D'Angelo V; Scarabino T; Liuzzi A
J Clin Endocrinol Metab; 1995 Aug; 80(8):2523-5. PubMed ID: 7629253
[TBL] [Abstract][Full Text] [Related]
11. In vivo measurement of dopamine receptors in pituitary adenomas using positron emission tomography.
Muhr C; Bergström M; Lundberg PO; Bergström K; Långström B
Acta Radiol Suppl; 1986; 369():406-8. PubMed ID: 2980511
[TBL] [Abstract][Full Text] [Related]
12. Carbon-11 epidepride: a suitable radioligand for PET investigation of striatal and extrastriatal dopamine D2 receptors.
Langer O; Halldin C; Dollé F; Swahn CG; Olsson H; Karlsson P; Hall H; Sandell J; Lundkvist C; Vaufrey F; Loc'h C; Crouzel C; Mazière B; Farde L
Nucl Med Biol; 1999 Jul; 26(5):509-18. PubMed ID: 10473189
[TBL] [Abstract][Full Text] [Related]
13. The discovery of epidepride and its analogs as high-affinity radioligands for imaging extrastriatal dopamine D(2) receptors in human brain.
de Paulis T
Curr Pharm Des; 2003; 9(8):673-96. PubMed ID: 12570798
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography in acromegaly and other pituitary adenoma patients.
Muhr C
Neuroendocrinology; 2006; 83(3-4):205-10. PubMed ID: 17047384
[TBL] [Abstract][Full Text] [Related]
15. Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography.
van Royen E; Verhoeff NF; Speelman JD; Wolters EC; Kuiper MA; Janssen AG
Arch Neurol; 1993 May; 50(5):513-6. PubMed ID: 8489409
[TBL] [Abstract][Full Text] [Related]
16. Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS).
Staedt J; Stoppe G; Kögler A; Riemann H; Hajak G; Munz DL; Emrich D; Rüther E
J Neural Transm Gen Sect; 1995; 99(1-3):187-93. PubMed ID: 8579804
[TBL] [Abstract][Full Text] [Related]
17. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease.
Tatsch K; Schwarz J; Oertel WH; Kirsch CM
Nucl Med Commun; 1991 Aug; 12(8):699-707. PubMed ID: 1838142
[TBL] [Abstract][Full Text] [Related]
18. The pituitary in nuclear medicine imaging.
Iglesias P; Cardona J; Díez JJ
Eur J Intern Med; 2019 Oct; 68():6-12. PubMed ID: 31519379
[TBL] [Abstract][Full Text] [Related]
19. D2-receptor imaging with [123I]IBZM and single photon emission tomography in psychiatry: a survey of current status.
Schlösser R; Schlegel S
J Neural Transm Gen Sect; 1995; 99(1-3):173-85. PubMed ID: 8579803
[TBL] [Abstract][Full Text] [Related]
20. SPECT tracer [(123)I]IBZM has similar affinity to dopamine D2 and D3 receptors.
Videbaek C; Toska K; Scheideler MA; Paulson OB; Moos Knudsen G
Synapse; 2000 Dec; 38(3):338-42. PubMed ID: 11020237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
